520-521 / 1778
Patient characteristics
Patients with Stage III EC
De Boer et al. Lancet Oncol 2018
5-year FFS for stage III: CTRT 69% vs RT 58%
5-year OS for stage III: CTRT 79% vs RT 70%
No. at risk (censored)
RT
CTRT
|
|
520-521 / 1778
Patient characteristics
Patients with Stage III EC
De Boer et al. Lancet Oncol 2018
5-year FFS for stage III: CTRT 69% vs RT 58%
5-year OS for stage III: CTRT 79% vs RT 70%
No. at risk (censored)
RT
CTRT